REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
1 hedge funds and large institutions have $2K invested in REGENERX BIOPHARMACEUTICALS in 2022 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
94% less capital invested
Capital invested by funds: $34K → $2K (-$32K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WJWM
Williams Jones Wealth Management
New York
|
-$40K |
RGN Hedge Fund Activity: Q1 2022 in Review
1 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q1 2022, worth a combined $2K — down 94% from $34K a quarter earlier.
Fund positioning in RGN was balanced in Q1 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Williams Jones Wealth Management, cutting an estimated $40K.
- 1 institutional investor held REGENERX BIOPHARMACEUTICALS (RGN) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $2K of REGENERX BIOPHARMACEUTICALS stock for Q1 2022, down 94% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q1 2022 and 0 closed out.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q1 2022 was Williams Jones Wealth Management, an estimated $40K sold.
Based on aggregated 13F filings for Q1 2022.